The University of Texas MD Anderson Cancer Center activated an investigator- initiated Phase 1b clinical trial of Soricimed Biopharma’s lead drug candidate, SOR-C13, in late-stage pancreatic cancer. The objectives of...
Zenabis Global (TSX:ZENA) received a cultivation license from Health Canada for its Zenabis Langley plant, adding 9,900 kg of licensed annual cultivation capacity of cannabis at Site A – Part 1 at the facility. The...
AC Immune (NASDAQ:ACIU) initiated a Phase 1b/2a clinical trial to evaluate its anti-phospho-Tau vaccine in patients with early Alzheimer’s disease (AD). Targeting pathological Tau, the vaccine is intended as a disease...
The European Commission (EC) granted X4 Pharmaceuticals’ (NASDAQ:XFOR) mavorixafor orphan drug designation for WHIM syndrome. WHIM stands for warts; hypogammaglobulinemia, or low antibody levels; infections; and...
BTIG downgraded Conformis (NASDAQ:CFMS) to “neutral” from “buy” following release of the company’s second quarter results. BTIG does not publish price targets on neutral-rated stocks. Conformis, which closed at $2.76 on...
Orchard Therapeutics’ (NASDAQ:ORTX) OTL-103 received FDA regenerative medicine advanced therapy (RMAT) designation for the treatment of Wiskott-Aldrich Syndrome (WAS). WAS is an inherited immune disorder where...
Therapix Biosciences (NASDAQ:TRPX) reported that Health Canada issued a product license for CannAmide as an anti-inflammatory, and for relief of chronic pain. CannAmide is an immediate release formulation of the...
BELLUS Health (TSX:BLU) enrolled the first patient in its Phase 2 study of BLU-5937 for the treatment of chronic cough. The study, called RELIEF, will assess the efficacy, safety, and tolerability of BLU-5937 at four...
Eloxx Pharmaceuticals (NASDAQ:ELOX) reported that the FDA cleared its IND for a Phase 2 trial of ELX-02 in patients with cystic fibrosis (CF). ELX-02 is a small molecule designed to restore production of CF...
Translate Bio (NASDAQ:TBIO) reported interim results from its Phase 1/2 clinical trial of MRT5005 in patients with cystic fibrosis (CF). MRT5005 is inhaled to deliver the gene that encodes functional CF transmembrane...
Closely-held MediBeacon and Huadong Medicine (SZ:000963) signed an agreement that will provide Huadong with exclusive rights to MediBeacon’s portfolio of assets in greater China. MediBeacon’s lead program is a point-of...
Hepion Pharmaceuticals (NASDAQ:HEPA) has partnered with Applied Pharmaceutical Innovation (API) to expand its research capabilities and further characterize its lead candidate, CRV431. API is an independent institute...
The FDA has authorized Hepion Pharmaceuticals (NASDAQ:HEPA) to proceed with its IND opening study of CRV431 for the treatment of non-alcoholic steatohepatitis (NASH). “Based on the preclinical and clinical studies we’ve...
Zenabis Global (TSX:ZENA) announced the licensing of Phase 2C – Part 1 at its Zenabis Atholville facility, adding an additional 9,800 kg of licensed annual cultivation capacity of cannabis. This licensing increases...
Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) enrolled the first patient in a Phase 2 clinical study of its light activated photodynamic compounds (PDC) in patients with non-muscle invasive bladder cancer (NMIBC) who...
Aeglea BioTherapeutics’ (NASDAQ:AGLE) pegzilarginase received FDA breakthrough therapy designation for the treatment of arginase 1 deficiency (ARG1-D). ARG1-D is a rare genetic childhood disease that causes severe...
Proteostasis Therapeutics (NASDAQ: PTI) dosed the first patient in a 28-day Phase 2 trial evaluating combinations of PTI-801, PTI-808 and PTI-428 for the treatment of cystic fibrosis (CF). CF is caused by a mutation in...
The FDA granted fast track and qualified infectious disease product (QIDP) designations to Matinas BioPharma’s (NYSE AMER:MTNB) MAT2203 for the treatment of cryptococcal meningitis. MAT2203 is a lipid nano-crystal...
Abeona Therapeutics (NASDAQ:ABEO) reported positive data from its ongoing Phase 1/2 clinical trial of ABO-102 for the treatment of Sanfilippo syndrome type A (MPS IIIA). Primarily affecting the central nervous system...
The German Federal Institute for Drugs and Medical Devices (BfArM) granted XPhyto Therapeutics’ German subsidiary, Bunker Pflanzenextrakte, a cannabis cultivation and extraction license for scientific purposes. Subject...
DelMar Pharmaceuticals (NASDAQ:DMPI) treated the first MGMT-unmethylated glioblastoma multiforme (GBM) patient in the adjuvant trial arm of its Phase 2 study of VAL-083. This study arm will enroll up to 24 newly...
Myovant Sciences (NASDAQ:MYOV) reported that the second of two Phase 3 studies of relugolix met its primary efficacy endpoint and six key secondary endpoints in women with uterine fibroids. Relugolix is a once daily...